Aflibercept for macular edema after branch retinal vein occlusion

Purpose The aim was to evaluate the real-world results of aflibercept in the treatment of macular edema due to branch retinal vein occlusion (BRVO) without prior treatment. Patients and methods The study included patients with treatment-naive symptomatic BRVO causing macular edema with a best correc...

Full description

Bibliographic Details
Main Author: Mahmoud Abouhussein
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Delta Journal of Ophthalmology
Subjects:
Online Access:http://www.djo.eg.net/article.asp?issn=1110-9173;year=2018;volume=19;issue=2;spage=140;epage=146;aulast=Abouhussein
id doaj-1c8234d857b24bc0a04000bd3eac6ac1
record_format Article
spelling doaj-1c8234d857b24bc0a04000bd3eac6ac12021-10-06T13:45:07ZengWolters Kluwer Medknow PublicationsDelta Journal of Ophthalmology1110-91732090-48352018-01-0119214014610.4103/DJO.DJO_84_17Aflibercept for macular edema after branch retinal vein occlusionMahmoud AbouhusseinPurpose The aim was to evaluate the real-world results of aflibercept in the treatment of macular edema due to branch retinal vein occlusion (BRVO) without prior treatment. Patients and methods The study included patients with treatment-naive symptomatic BRVO causing macular edema with a best corrected visual acuity (VA) of 0.1 or better, central macular thickness (CMT) of more than 300 μm, and a duration less of than 6 months. Patients received intravitreal 2.0 mg of aflibercept. Follow-up examinations were performed monthly after the first injection for at least 6 months. At each visit, complete examination and optical coherence tomography scans were performed with recording of the best corrected VA and CMT on optical coherence tomography. At the monthly follow-up visits, additional Aflibercept injections were given as needed (pro-re-nata) when intraretinal/subretinal fluid was still present. Results A total of 25 patients were included in the study. Their age ranged from 42 to 75 years with a mean of 61.12±8.34 years. There were 16 men and nine women. Duration of vein occlusion ranged from 10 to 50 days with a mean of 21.8±12.29 days. Baseline logarithm of the minimal angle of resolution VA mean was 0.790±0.16. It improved at the 6-month follow-up visit to 0.244±0.22, which was statistically significant (P=0.001). Baseline CMT mean was 538.84±186.96 µm. It improved at the end of follow-up to 284.680±68.22 µm, which was statistically significant (P=0.001). Conclusion Aflibercept given with pro-re-nata regimen was safe and effective in the treatment of macular edema after BRVO.http://www.djo.eg.net/article.asp?issn=1110-9173;year=2018;volume=19;issue=2;spage=140;epage=146;aulast=Abouhusseinafliberceptbranch retinal vein occlusionmacular edema
collection DOAJ
language English
format Article
sources DOAJ
author Mahmoud Abouhussein
spellingShingle Mahmoud Abouhussein
Aflibercept for macular edema after branch retinal vein occlusion
Delta Journal of Ophthalmology
aflibercept
branch retinal vein occlusion
macular edema
author_facet Mahmoud Abouhussein
author_sort Mahmoud Abouhussein
title Aflibercept for macular edema after branch retinal vein occlusion
title_short Aflibercept for macular edema after branch retinal vein occlusion
title_full Aflibercept for macular edema after branch retinal vein occlusion
title_fullStr Aflibercept for macular edema after branch retinal vein occlusion
title_full_unstemmed Aflibercept for macular edema after branch retinal vein occlusion
title_sort aflibercept for macular edema after branch retinal vein occlusion
publisher Wolters Kluwer Medknow Publications
series Delta Journal of Ophthalmology
issn 1110-9173
2090-4835
publishDate 2018-01-01
description Purpose The aim was to evaluate the real-world results of aflibercept in the treatment of macular edema due to branch retinal vein occlusion (BRVO) without prior treatment. Patients and methods The study included patients with treatment-naive symptomatic BRVO causing macular edema with a best corrected visual acuity (VA) of 0.1 or better, central macular thickness (CMT) of more than 300 μm, and a duration less of than 6 months. Patients received intravitreal 2.0 mg of aflibercept. Follow-up examinations were performed monthly after the first injection for at least 6 months. At each visit, complete examination and optical coherence tomography scans were performed with recording of the best corrected VA and CMT on optical coherence tomography. At the monthly follow-up visits, additional Aflibercept injections were given as needed (pro-re-nata) when intraretinal/subretinal fluid was still present. Results A total of 25 patients were included in the study. Their age ranged from 42 to 75 years with a mean of 61.12±8.34 years. There were 16 men and nine women. Duration of vein occlusion ranged from 10 to 50 days with a mean of 21.8±12.29 days. Baseline logarithm of the minimal angle of resolution VA mean was 0.790±0.16. It improved at the 6-month follow-up visit to 0.244±0.22, which was statistically significant (P=0.001). Baseline CMT mean was 538.84±186.96 µm. It improved at the end of follow-up to 284.680±68.22 µm, which was statistically significant (P=0.001). Conclusion Aflibercept given with pro-re-nata regimen was safe and effective in the treatment of macular edema after BRVO.
topic aflibercept
branch retinal vein occlusion
macular edema
url http://www.djo.eg.net/article.asp?issn=1110-9173;year=2018;volume=19;issue=2;spage=140;epage=146;aulast=Abouhussein
work_keys_str_mv AT mahmoudabouhussein afliberceptformacularedemaafterbranchretinalveinocclusion
_version_ 1716840663574642688